# [18F]ACI-15916 PET in α-synucleinopathies

> **NCT06891703** · EARLY_PHASE1 · RECRUITING · sponsor: **AC Immune SA** · enrollment: 46 (estimated)

## Conditions studied

- Parkinson's Disease (PD)
- Multiple System Atrophy (MSA)
- Dementia With Lewy Bodies (DLB)

## Interventions

- **OTHER:** [18F]ACI-15916

## Key facts

- **NCT ID:** NCT06891703
- **Lead sponsor:** AC Immune SA
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-20
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06891703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06891703, "[18F]ACI-15916 PET in α-synucleinopathies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06891703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*